One of the main changes in the 2025 update on the EULAR guidelines for imaging in SpA is that of MRI replacing CR as the initial imaging modality while CR & low dose CT of SIJs became alternative modalities in the absence of or if with CIs to MRI AbsPOS0682 @RheumNow #EULAR2026 https://t.co/bj2NWKnIGf

Treat-to-target in inflammatory arthritis recommended by every guideline. Followed in only 40% of SpA visits. The main reason was activity simply wasn’t documented using a validated index. You can’t target what you don’t measure. Abstr 0351 @ RheumNow #EULAR2026 #axSpA #PsA https://t.co/VAcoZfCXsR

New Insights in Gout Clinical Management https://t.co/Eo63NUhaY2 https://t.co/oHZG1c1LhL

CAR-T Cell Therapies in Refractory RMD Current therapies for rheumatoid arthritis rely on sustained immunosuppression rather than restoration of immune tolerance, with off-drug remission remaining rare. Recent anecdotal reports suggest that CD19-directed CAR-T cell therapy may https://t.co/lXX5RjEw6a

JAK Safety Debate Continues: Stronger VTE signal, less clear cancer signal Few topics in rheumatology have reshaped prescribing behavior as dramatically as the safety concerns surrounding JAK inhibitors following ORAL Surveillance and the subsequent FDA and EMA warnings. Even https://t.co/wfQZn1hO3N

Getting #RA and IA diagnosed faster: UK RheumACaN program (integrated education + pathway redesign) ↑ clinician confidence 4.4 to 8.6/10. Referral within 3 days: 52% → 70%, with sustained improvement. Education that translates to real outcomes. @RheumNow #EULAR2026 POS0784 https://t.co/1Va9rkLBHM

#EULAR2026 OP0220 How can we improve physical function of #SLE patients? Cross-sectional study of 2 US cohorts: poor physical function was associated with Fatigue, depression, learned helplessness and perceived stress. We should focus on improving fatigue & wellbeing @RheumNow https://t.co/vAFqYyuzgN

Proud to present POS0784 at #EULAR2026. RheumACaN education + pathway redesign across primary and secondary care improved early inflammatory arthritis referrals within 3 working days from 52% to 70%, exceeding the national benchmark. 95% of clinicians changed their practice. https://t.co/W6VViVRndp

EULAR 2026 Daily Recap LIVE By Day 3, the biggest stories of EULAR begin to emerge. Join Dr. Jack Cush and https://t.co/V10S4oVFsv faculty for a fast-paced review of the studies, debates, and breakthrough findings that rheumatologists will be discussing long after the meeting https://t.co/7hvwCkUz9C

⏰ The question rheumatologists keep asking: Does early axSpA diagnosis reduce long-term spinal damage? Answer from the SCQM registry (n=376): Early diagnosis linked to 3.85 fewer mSASSS points long-term, esp. in HLA-B27+ males #POS0191 #EULAR2026 @RheumNow https://t.co/HM5kvqXMEh